Helix BioPharma Corp. (OTCMKTS:HBPCF - Get Free Report) fell 11.6% during mid-day trading on Tuesday . The stock traded as low as $0.65 and last traded at $0.65. 2,900 shares were traded during mid-day trading, an increase of 136% from the average session volume of 1,228 shares. The stock had previously closed at $0.74.
Helix BioPharma Price Performance
The firm's 50-day moving average price is $0.86 and its 200 day moving average price is $0.40. The firm has a market capitalization of $159.32 million, a price-to-earnings ratio of -32.50 and a beta of 0.02.
About Helix BioPharma
(
Get Free Report)
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Helix BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.
While Helix BioPharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
